Supernus Pharmaceuticals Inc's treatment for attention deficit hyperactivity disorder met the main goal of two trials, but shares fell about 16 percent on Thursday as the data failed to convince some investors that the drug was better than rivals.


40


Reuters

Latest News

Haaretz: The Latest: White House slams contempt vote for officials

Haaretz: The Latest: Illinois jury goes home without sentence verdict

Haaretz: For U.S. Republican senator, Trump went 'over the line' on Twitter attacks

Haaretz: Solano, Giants complete four-game sweep of Rockies

Haaretz: Fed-up Puerto Ricans march demanding governor resign

Haaretz: FEATURE -Bullied by peers, India's LGBT+ children drop out of schools

Haaretz: UK lawmakers to count environmental cost of mass tourism

Haaretz: UPDATE 2-Trump meets Chinese Uighur, other religious persecution victims at White House

Haaretz: UPDATE 8-MLB Results

Haaretz: US heat wave just warming up for long and scorching weekend

Haaretz: House blocks maverick Democrat's Trump impeachment effort

Haaretz: House holds 2 Trump officials in contempt in census dispute

Haaretz: U.S. House rejects Saudi weapons sales; Trump to veto

Haaretz: De Blasio beats back calls to fire officer in Garner death

Haaretz: 'Wonderful Life' stage adaptation gets a little help from Paul McCartney

Haaretz: Rays-Yankees postponed, DH on Thursday

Haaretz: Solano, Giants complete four-game sweep of Rockies

Haaretz: Fed-up Puerto Ricans march demanding governor resign

Haaretz: Phillies P Neris draws suspension for hitting Freese

Haaretz: Jury deliberates death penalty in Chinese scholar's slaying

Haaretz: Asylum seekers anxiously cross into U.S. as new policy kicks in

Haaretz: Family mourns 6-year-old girl killed by father's golf shot

Haaretz: UPDATE 2-U.S. House holds Barr, Ross in criminal contempt over census documents

19 Related Articles from 2018-12-06